Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

Sarret Joseph J.

2. Date of Event Requiring Statement (Month/Day/Year)
04/21/2010

3. Issuer Name and Ticker or Trading Symbol
CODEXIS INC [CDXS]

(Last)

(First)

(Middle)

C/O CODEXIS, INC., 200 PENOBSCOT DRIVE

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	_____ 10% Owner
__X__ Officer (give title below)	_____ Other (specify below)
CBO, President Pharmaceuticals

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

REDWOOD CITY, CA 94063

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,333 ⁽¹⁾	I	See Footnote ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽³⁾	08/11/2015	Common Stock	36,666 ⁽¹⁾	$ 1.05 ⁽¹⁾	D
Stock Option (right to buy)	⁽⁴⁾	01/26/2017	Common Stock	53,333 ⁽¹⁾	$ 2.45 ⁽¹⁾	D
Stock Option (right to buy)	⁽⁵⁾	08/28/2017	Common Stock	19,666 ⁽¹⁾	$ 6.71 ⁽¹⁾	D
Stock Option (right to buy)	⁽⁶⁾	10/25/2017	Common Stock	40,000 ⁽¹⁾	$ 6.86 ⁽¹⁾	D
Stock Option (right to buy)	⁽⁷⁾	06/02/2019	Common Stock	37,000 ⁽¹⁾	$ 7.46 ⁽¹⁾	D
Stock Option (right to buy)	⁽⁸⁾	06/02/2019	Common Stock	13,333 ⁽¹⁾	$ 7.46 ⁽¹⁾	D
Stock Option (right to buy)	⁽⁹⁾	11/09/2019	Common Stock	120,000 ⁽¹⁾	$ 9.09 ⁽¹⁾	D
Stock Option (right to buy)	⁽¹⁰⁾	03/11/2020	Common Stock	33,333 ⁽¹⁾	$ 11.87 ⁽¹⁾	D

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Sarret Joseph J. C/O CODEXIS, INC. 200 PENOBSCOT DRIVE REDWOOD CITY, CA 94063			CBO, President Pharmaceuticals

Signatures

/s/ Joseph J. Sarret		04/21/2010
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Reflects a 2-for-3 reverse stock split of the Issuer's outstanding securities effected immediately prior to the effectiveness of the Issuer's S-1 Registration Statement (Commission File No. 333-164044).
(2)	Shares held by Joseph Sarret as Trustee UTD 5/30/00.
(3)	100% of the shares subject to the option are fully vested and exercisable.
(4)	Option vests with respect to 25% of the shares subject thereto on January 26, 2008, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on January 26, 2011.
(5)	Option vests with respect to 25% of the shares subject thereto on August 28, 2008, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on August 28, 2011.
(6)	Option vests with respect to 25% of the shares subject thereto on October 25, 2008, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on October 25, 2011.
(7)	Option vests with respect to 25% of the shares subject thereto on March 1, 2010, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on March 1, 2013.
(8)	Option vests with respect to 1/24th of the shares subject thereto monthly commencing on January 1, 2011, such that the option will be fully vested and exercisable on January 1, 2013.
(9)	Option vests with respect to 25% of the shares subject thereto on October 16, 2010, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on October 16, 2013.
(10)	Option vests with respect to 100% of the shares subject thereto on January 1, 2015. Upon the completion of the Issuer's initial public offering, the option will vest with respect to 25% of the shares subject thereto on January 1, 2011, with 1/48th of the shares vesting monthly thereafter, such that the option will be fully vested and exercisable on January 1, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.